Navigation Links
Phytomedics, Inc. Awarded QTDP Grant from U.S. Department of Health and Human Services

JAMESBURG, N.J., Nov. 9, 2010 /PRNewswire/ -- Phytomedics, Inc., a transformational healthcare company developing a novel portfolio of drugs and consumer products solely derived from plant sources, announced today that it has been awarded a grant in the amount of $244,000 under the Qualifying Therapeutic Discovery Project (QTDP) Program to advance the development of its lead product PMI-001 for Rheumatoid Arthritis.  PMI-001 is presently in Phase 2b/3 development.



Dr. Laurie Smaldone, Phytomedics President & CEO, commented: "We are very appreciative of the recognition and support provided by this award which we believe affirms that PMI-001 has the potential to address the significant unmet medical needs in Rheumatoid Arthritis."

The QTDP grant program provides support for innovative projects that are determined by the U.S. Department of Health and Human Services to have reasonable potential to result in a new therapy, reduce health care costs, or significantly advance the goal of curing cancer.

PMI-001 is a novel, oral, disease-modifying, botanical drug for use in patients with Rheumatoid Arthritis (RA).  Three U.S. based, clinical trials, including a recently published and compelling 6 month Phase 2b/3 study, have demonstrated efficacy in the range of the intravenous biologic therapies, as a stand-alone therapy in reducing signs and symptoms of RA at all American College of Rheumatology (ACR) endpoints with rapid onset of action (as early as 2 weeks), and the ability to halt joint erosions and narrowing (at 6 months), with an acceptable side effect profile.

Combined with the fact that this drug product is delivered as an oral dosage form, and behaves as a steroid-mimetic without corticosteroid side effects, makes PMI-001 a game changing therapeutic opportunity in RA, as well as in the wider autoimmune disease therapeutic category.

About Phytomedics

Phytomedics, Inc. is a transformational healthcare company developing a novel portfolio of drugs and consumer products solely derived from plant sources. Through its proprietary technology platform, the Company has produced a broad pipeline of lead product candidates, several of which are in clinical development. The company's lead candidate, PMI-001, is a novel, oral, disease modifying anti-rheumatic drug currently being developed as a natural pharmaceutical alternative in rheumatoid arthritis therapy.

SOURCE Phytomedics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Epeius Biotechnologies Awarded Federal Grant Advancing Tumor-Targeted Cancer Therapy
2. Medrium Awarded Electronic Health Record (EHR) Module Certification by Drummond Group
3. NovaSperse(SM) Nanoparticle Innovator, PharmaNova, Inc., Awarded Four Government Grants Toward Development of New Therapeutic Products Under Congressional Qualifying Therapeutic Discovery Project Initiative
4. Parascript Awarded $244,479.25 Affordable Care Act Grant From the U.S. Government
5. WuXi PharmaTech Awarded GLP Certificate from SFDA for Suzhou Toxicology Facility
6. Neuraltus Pharmaceuticals Awarded $733,437 Under the Qualifying Therapeutic Discovery Projects Grant Program (QTDP)
7. Inspiration Biopharmaceuticals Awarded Two Grants Under the Qualifying Therapeutic Discovery Projects Grant Program (QTDP)
8. Pervasis Therapeutics Awarded Four Grants Under the Qualifying Therapeutic Discovery Project
9. NeoGenomics Awarded $374,000 in R&D Grants from the US Government
10. NuView Life Sciences Awarded Grants Under the Patient Protection and Affordable Care Act of 2010
11. ECRI Institute Awarded AHRQ Contract to Establish National Healthcare Horizon Scanning System
Post Your Comments:
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... WAYNE, Pa. , June 23, 2016 ... provider, will launch its next generation clinical outcomes platform, Bracket ... DIA Meeting held on June 26 – 30, 2016 in ... 6.0, the first electronic Clinical Outcome Assessment product of its ... DIA Booth #715. Bracket eCOA 6.0 is a ...
Breaking Medicine Technology:
(Date:6/27/2016)... Viejo, California (PRWEB) , ... June 27, 2016 , ... ... are fully customizable inside of Final Cut Pro X," said Christina Austin - CEO ... another unique style. Final Cut Pro X users can now reveal the ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... its strategic partnership with Connance, a healthcare industry leader providing predictive analytics ... proprietary technology combine to provide health systems, hospitals and ambulatory surgical centers ...
(Date:6/27/2016)... , ... June 27, 2016 , ... recently awarded ... Eyeglasses . , Millions of individuals in the United States and Canada wear ... a way to both correct vision and make a fashion statement. Even celebrities use ...
(Date:6/26/2016)... Battle Creek, Michigan (PRWEB) , ... June 26, 2016 , ... ... abuse, joined as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table ... held in honor of the city’s history as home to some of the world’s ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned ... developed to enhance the health of felines. The formula is all-natural and is made ... in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root ...
Breaking Medicine News(10 mins):